Lv1
50 积分 2023-08-31 加入
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial
2天前
已完结
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
3天前
已完结
Lung cancer
1个月前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Bispecific antibody platforms for cancer immunotherapy
1个月前
已完结
Opportunities and challenges of bi-specific antibodies
1个月前
已完结
Trends and Challenges in Bispecific Antibody Production
1个月前
已完结
The emerging role of local therapy in oligometastatic non–small cell lung cancer
1个月前
已完结
Oligometastasis: Past, Present, Future
1个月前
已完结
Engineering bispecific antibodies
1个月前
已完结
皖公网安备34019202002308
